Touchstone
Last syncNov 1, 2026, 6:55 PM ET

NBIX

Neurocrine Biosciences Inc Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$146.10Close $14.6BMarket cap $123.10 – $185.5052-week range Nov 2, 2026Next report · after the close

Highlights

Strengths

  • Tight base near its pivot pullbacks 20% → 15% → 10%; 0.6% below its $146.92 pivot
  • Earnings growing EPS +30% year on year

Cautions

  • Not in an uptrend 3 of 8 trend conditions
  • Lagging the market RS 43 · weaker than 57% of stocks over 12 months
  • Results soon Nov 2, 2026, in 1 day

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Jul 31, 2026
Off 12-month high 21%
1wk up 2.4% price change
1mo up 3.0% price change
12-month return up 6% market up 11% · its own down 5%
F-score 6 / 9 Mixed
Altman Z 8.02 Low risk
P/E 30.6× price / earnings
PEG 0.73 P/E / EPS growth
P/B 4.5× price / book
Earnings yield up 4.5% EBIT / enterprise value
Cheaper than 56% of the market · around average
Revenue growth up 21% year on year
EPS growth up 30% latest quarter · -2353 pts
Sales growth up 39% latest quarter · -3 pts
ROE up 16% return on equity
Free cash margin up 26% $748.7M FCF
D/E — long-term debt / equity
Net debt / EBITDA -1.2× net cash
Interest cover —EBIT / interest
Piotroski tests
  • short-term liquidity weakened
  • issued more shares
  • gross margin narrowed
  • profitable on its assets
  • generating cash from operations
  • profitability improving
  • profits backed by cash
  • reduced long-term debt
  • assets working harder

Trade setup

ATR% 2.4% $3.45 a day · 2×ATR $139.20
RS 43 / 99 vs the universe
Trend 3 / 8 trend template
Relative volume 1.1× vs 50-day average
Up/down volume 0.87 50 sessions
Implied move — no option chain · report Nov 2, 2026
Contractions 3 20% → 15% → 10%
Pivot $146.92 0.6% below
Volume dry-up 0.9× 10 vs 50 sessions
Trend template · 3 of 8
  • Price above the 150 and 200-day averages: fails
  • 150-day average above the 200-day: passes
  • 200-day average rising for a month: passes
  • 50-day average above the 150 and 200-day: fails
  • Price above the 50-day average: fails
  • At least 30% above the 52-week low: fails
  • Within 25% of the 52-week high: passes
  • RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Jul 30, 2026
Last shock Jul 31, 2026-10% in one session3.6× volumeon results-12% since

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $2.9B +21% on FY2024
$0 $5B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $1.0B FY2021 · $1.1B FY2022 · $1.5B FY2023 · $1.9B FY2024 · $2.4B FY2025 · $2.9B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $478.6M +40% on FY2024
$0 $500M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $407.3M FY2021 · $89.6M FY2022 · $154.5M FY2023 · $249.7M FY2024 · $341.3M FY2025 · $478.6M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $748.7M +34% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $217.6M FY2021 · $233.1M FY2022 · $322.9M FY2023 · $361.6M FY2024 · $557.2M FY2025 · $748.7M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 98%
  • Net 17%
  • Free cash 26%
0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 99% · Net 39% · Free cash 21% FY2021 · Gross 99% · Net 8% · Free cash 21% FY2022 · Gross 98% · Net 10% · Free cash 22% FY2023 · Gross 98% · Net 13% · Free cash 19% FY2024 · Gross 99% · Net 14% · Free cash 24% FY2025 · Gross 98% · Net 17% · Free cash 26%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $187.1M FY2021 · Cash $340.8M FY2022 · Cash $262.9M FY2023 · Cash $251.1M FY2024 · Cash $233.0M FY2025 · Cash $713.0M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 100.10m +7.1% since FY2020
100.10m 93.50m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 93.50m FY2021 · 94.90m FY2022 · 96.50m FY2023 · 98.70m FY2024 · 99.40m FY2025 · 100.10m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $1.0B $1.1B $1.5B $1.9B $2.4B $2.9B
Gross margin 99% 99% 98% 98% 99% 98%
Operating income $163.0M $102.5M $249.0M $250.9M $570.5M $619.1M
Net income $407.3M $89.6M $154.5M $249.7M $341.3M $478.6M
Net margin 39% 8% 10% 13% 14% 17%
Earnings per share $4.16 $0.92 $1.56 $2.47 $3.29 $4.67
Free cash flow $217.6M $233.1M $322.9M $361.6M $557.2M $748.7M
Free cash margin 21% 21% 22% 19% 24% 26%
Cash $187.1M $340.8M $262.9M $251.1M $233.0M $713.0M
Shareholders' equity $1.1B $1.4B $1.7B $2.2B $2.6B $3.3B
Shares outstanding 93.50m 94.90m 96.50m 98.70m 99.40m 100.10m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Jul 31, 2026 Quarterly ↗ Jun 30, 2026 31d
May 5, 2026 Quarterly ↗ Mar 31, 2026 35d
Feb 11, 2026 Annual ↗ Dec 31, 2025 42d
Oct 28, 2025 Quarterly ↗ Sep 30, 2025 28d
Jul 30, 2025 Quarterly ↗ Jun 30, 2025 30d
May 5, 2025 Quarterly ↗ Mar 31, 2025 35d
Feb 10, 2025 Annual ↗ Dec 31, 2024 41d
Oct 30, 2024 Quarterly ↗ Sep 30, 2024 30d
Aug 1, 2024 Quarterly ↗ Jun 30, 2024 32d
May 1, 2024 Quarterly ↗ Mar 31, 2024 31d
Feb 9, 2024 Annual ↗ Dec 31, 2023 40d
Oct 31, 2023 Quarterly ↗ Sep 30, 2023 31d

Current reports

FiledDisclosed
Sep 28, 2026 Director or officer change ↗
Jul 30, 2026 Results ↗
May 28, 2026 Director or officer change · Shareholder vote ↗
May 18, 2026 Material agreement · Acquisition or disposal · New obligation · Regulation FD ↗
May 5, 2026 Results ↗
Apr 6, 2026 Material agreement ↗
Feb 11, 2026 Results ↗
Nov 24, 2025 Director or officer change ↗
Oct 28, 2025 Results ↗
Jul 30, 2025 Results ↗
May 30, 2025 Director or officer change ↗
May 22, 2025 Director or officer change · Shareholder vote ↗